Standard BioTools Inc. (LAB)
Largest Insider Buys in Sector
LAB Stock Price History Chart
LAB Stock Performance
About Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Insider Activity of Standard BioTools Inc.
Over the last 12 months, insiders at Standard BioTools Inc. have bought $18.49M and sold $0 worth of Standard BioTools Inc. stock.
On average, over the past 5 years, insiders at Standard BioTools Inc. have bought $8.89M and sold $514,009 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Casdin Partners Master Fund, L.P. () — $110.93M.
The last purchase of 250,000 shares for transaction amount of $546,750 was made by Casdin Partners Master Fund, L.P. () on 2024‑08‑27.
List of Insider Buy and Sell Transactions, Standard BioTools Inc.
| 2024-08-27 | 250,000 0.0798% | $2.19 | $546,750 | -13.30% | ||||
| 2024-08-26 | 150,000 0.0471% | $2.15 | $322,455 | -12.90% | ||||
| 2024-08-23 | 292,100 0.0907% | $2.13 | $620,975 | -11.68% | ||||
| 2024-08-22 | 307,900 0.088% | $1.96 | $602,807 | -2.82% | ||||
| 2024-08-21 | 500,000 0.139% | $1.90 | $951,950 | -2.06% | ||||
| 2024-08-20 | 500,000 0.1368% | $1.87 | $936,700 | +2.15% | ||||
| 2024-08-19 | 250,000 0.0676% | $1.85 | $463,225 | -0.52% | ||||
| 2024-08-14 | 1.2M 0.2794% | $1.59 | $1.91M | +22.26% | ||||
| 2024-08-13 | 550,000 0.13% | $1.62 | $890,560 | +15.95% | ||||
| 2024-08-12 | 500,000 0.1198% | $1.64 | $820,600 | +18.87% | ||||
| 2024-08-09 | 525,408 0.1239% | $1.61 | $848,481 | +16.67% | ||||
| 2024-08-08 | 569,562 0.1362% | $1.64 | $932,601 | +13.17% | ||||
| 2024-08-07 | 500,000 0.1148% | $1.57 | $786,200 | +19.62% | ||||
| 2024-08-05 | 200,000 0.0462% | $1.58 | $316,780 | +18.87% | ||||
| 2024-08-02 | 1M 0.2382% | $1.63 | $1.63M | +14.24% | ||||
| 2024-05-23 | 100,000 0.038% | $2.60 | $260,000 | -26.44% | ||||
| 2024-05-22 | 150,000 0.0566% | $2.58 | $387,735 | -25.87% | ||||
| 2024-05-21 | 350,000 0.1308% | $2.56 | $895,930 | -25.58% | ||||
| 2024-05-20 | 100,000 0.0377% | $2.58 | $258,130 | -25.58% | ||||
| 2024-05-17 | 352,072 0.1317% | $2.56 | $902,044 | -25.10% |
Insider Historical Profitability
| Casdin Partners Master Fund, L.P. | 54025821 14.513% | $1.69 | 27 | 0 | +12.56% | |
| Caligan Partners LP | 10 percent owner | 11444836 3.0744% | $1.69 | 18 | 0 | <0.0001% |
| JOHNSON DAVID EDWARD | 11189663 3.0059% | $1.69 | 8 | 0 | <0.0001% | |
| LEVIN CAPITAL STRATEGIES, L.P. | 10 percent owner | 10473809 2.8136% | $1.69 | 111 | 0 | +23.89% |
| Levin Easterly Partners LLC | 10 percent owner | 6909871 1.8562% | $1.69 | 0 | 18 | |
| TORRAY ROBERT E | director | 2381164 0.6397% | $1.69 | 4 | 0 | |
| HAYWARD ALFRED O JR | CEO of LaBranche & Co LLC | 1881468 0.5054% | $1.69 | 1 | 0 | |
| LABRANCHE GEORGE M L IV | Chairman, CEO & President | 1300000 0.3492% | $1.69 | 0 | 1 | |
| Casdin Eli | 1200000 0.3224% | $1.69 | 3 | 0 | +12.56% | |
| MURPHY ROBERT M | CEO of LaBranche & Co. LLC | 821110 0.2206% | $1.69 | 0 | 4 | |
| BURKE WILLIAM J III | Chief Operating Officer | 571036 0.1534% | $1.69 | 4 | 0 | |
| COLELLA SAMUEL D | director | 161109 0.0433% | $1.69 | 11 | 5 | +11.04% |
| BARTHELEMY NICOLAS | director | 149373 0.0401% | $1.69 | 2 | 1 | +82.84% |
| Linthwaite Stephen Christopher | President & CEO | 145347 0.039% | $1.69 | 3 | 1 | +13.41% |
| Black Jeffrey G. | SVP & Chief Financial Officer | 85984 0.0231% | $1.69 | 2 | 0 | +7.31% |
| JONES EVAN/ FA | director | 53551 0.0144% | $1.69 | 9 | 9 | +16.87% |
| JOG VIKRAM | CHIEF FINANCIAL OFFICER | 52061 0.014% | $1.69 | 1 | 26 | +89.16% |
| McPhail Steven | Chief Commercial Officer | 27842 0.0075% | $1.69 | 1 | 0 | +89.16% |
| Worthington Gajus Vincent | PRESIDENT & CEO | 6815 0.0018% | $1.69 | 0 | 55 | |
| ROBBINS STUART M | director | 5000 0.0013% | $1.69 | 1 | 0 | |
| Yow Mai Chan | See Remarks | 1516 0.0004% | $1.69 | 0 | 13 | |
| Smith William Maxwell | EVP, LEGAL AFFAIRS & GC | 1389 0.0004% | $1.69 | 1 | 64 | <0.0001% |
| JONES ROBERT C | EVP, RESEARCH & DEVELOPMENT | 947 0.0003% | $1.69 | 0 | 18 | |
| Walder Fredric T | CHIEF OPERATING OFFICER | 0 0% | $1.69 | 0 | 5 |